Product news

Share this article:
The FDA has broadened the US indication for Novartis' once-yearly Reclast (zoledronic acid) injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions